This article examines the factors related to side effects, re-sting reactions, and adherence in venom immunotherapy (VIT) for venom allergies. The study reveals that side effects during VIT are more likely in females, with honeybee venom, and in cases where the initial sting reaction was severe. Re-sting reactions after completing VIT are also associated with side effects during treatment. The study emphasizes the importance of considering these factors when determining the duration of VIT and the need for lifelong treatment in certain cases. The study also explores adherence to VIT and the risk factors for allergic reactions in patients with insect venom allergy. It finds that re-sting during VIT is reported in a significant number of cases, and side effects during VIT are linked to allergic reactions after re-sting. The study also reveals high adherence to VIT and adrenaline autoinjector (AAI) use, but low adherence to AAI when VIT is prematurely terminated. Risk factors for side effects during VIT include honeybee venom, female sex, and severe initial sting reactions. The study acknowledges limitations such as self-reported data and non-standardized procedures for re-sting. [Extracted from the article]